|Budget Amount *help
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2013: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2012: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2011: ¥2,730,000 (Direct Cost: ¥2,100,000、Indirect Cost: ¥630,000)
Serum samples were collected from 11 infants with ROP who had received intravitreal bevacizumab injection before and 1 day, 1 week, and 2 weeks after the injection. The serum concentrations of bevacizumab and VEGF were measured by enzyme-linked immunosorbent assay. As a result, the serum concentration of bevacizumab before and 1 day, 1week, and 2 weeks after a total of 0.5 mg of intravitreal bevacizumab was 0, 195, 946L, and 1214 (ng/mL), respectively. The serum concentration of VEGF before and 1 day, 1 week, and 2 weeks after a totalof 0.5 mg intravitreal bevacizumab was 1628, 427, 246, and 269 (pg/mL), respectively. There was a significant negative correlation (r= 0.575, P=0.0125) between the serum concentration of bevacizumab and VEGF. These results indicate that bevacizumab can escape from the eye into the systemiccirculation and reduce the serum level of VEGF in infants with ROP.